CAPScall of the Week: Clovis Oncology Inc (CLVS)

Page 1 of 2

For years, satirical late-night TV host Stephen Colbert has been running a series on his show called “Better Know a District,” which highlights one of the 435 U.S. congressional districts and its representative. While I am no Stephen Colbert, I am brutally inquisitive when it comes to the 5,000-plus listed companies on the U.S. stock exchanges.

That’s why I’ve made it a weekly tradition to examine one seldom-followed company within the Motley Fool CAPS database, and make a CAPScall of outperform or underperform on that company.

For this week’s round of “Better Know a Stock,” I’m going to take a closer look at Clovis Oncology Inc (NASDAQ:CLVS).

Clovis Oncology Inc (NASDAQ:CLVS)What Clovis Oncology does
As Clovis Oncology Inc (NASDAQ:CLVS)’ name would imply, there’s no smoke-and-mirror tricks here regarding what it does: It’s a biotechnology company engaged in researching anti-cancer compounds. It has three compounds currently in its pipeline: CO-1686 — which is an oral phase I/II epidermal growth factor receptor, or EGFR, inhibitor for the treatment of non-small-cell lung cancer, or NSCLC — that it’s partnered with Roche Holding Ltd. (ADR) (PINK:RHHBY) in developing; Rucaparib — which is a poly ADP-ribose polymerase, or PARP, inhibitor in phase I/II trials for ovarian and breast cancer; and a preclinical cKIT inhibitor for gastrointestinal stromal tumors that it’s partnered with Array Biopharma Inc (NASDAQ:ARRY) on.

In Clovis Oncology Inc (NASDAQ:CLVS)’ most recently ended fourth quarter, it reported a loss of $21.1 million compared to a loss of just $14.9 million in the year-ago period as its total cash level rose modestly to $144.1 million from the $140.2 million it ended with in 2011.

Whom it competes against
This is one of those cases where I say there are a ton of competitors in NSCLC, but few that target the T790M mutation that CO-1686 is being developed to treat. In fact, there are no FDA-approved treatments to specifically target the mutation at the moment. However, that may change very shortly as Boehringer Ingelheim does have an experimental drug known as Afatinib under an accelerated FDA review for EGFR mutation-positive NSCLC. With Clovis still early in its development, Afatinib could have a chance to clean up before CO-1686 even gets to late-stage enrollment.

Something similar can be said for Clovis Oncology Inc (NASDAQ:CLVS)’ competition in breast cancer with regard to PARP inhibitors. However, unlike with NSCLC, advancements in PARP inhibitors are still very slow, so a drug like Rucaparib that is still being studied in phase 1 trials has just as much chance of success as AbbVie Inc (NYSE:ABBV)‘s Veliparib, which is being tested as a combination PARP inhibiting therapy in phase 1/2 trials.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!